Product Description
WVE-N531 is Waves first exon skipping candidate, and the first candidate systemically administered by intravenous infusion, to utilize its novel PN backbone chemistry modifications.
Mechanisms of Action: Exon 53 Inhibitor
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Wave Life Sciences
Company Location: SINGAPORE U0 018936
Company CEO: Paul B. Bolno
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Jordan, United Kingdom
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Muscular Dystrophy, Duchenne
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| FORWARD-53 | P2 |
Active, not recruiting |
Muscular Dystrophy, Duchenne |
2025-01-01 |
24% |